Scancell Holdings Plc (SCNLF)
OTC PINK OTC PINK Primary 
Scancell advances cancer immunotherapy trial with new dosing approach for advanced melanoma
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has begun dosing patients in a new arm of its ongoing phase II trial, exploring an updated method for delivering its next-generation cancer immunotherapy for advanced melanoma. Known as Cohort 4, the study will assess intradermal administration and an accelerated dosing schedule of Scancell's iSCIB1+ Immunobody therapy, which is designed to stimulate the immune system to attack tumours.
Scancell joins NHS Cancer Vaccine Launchpad - ICYMI
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L'Huillier talked with Proactive about the company's partnership with the NHS Cancer Vaccine Launchpad to accelerate patient recruitment for its SCOPE study evaluating the iSCIB1+ DNA cancer vaccine. L'Huillier described the deal as “a very positive endorsement for Scancell and for the medicines that we are developing,” noting that the therapy is showing promise in delivering long-term immune control in advanced melanoma patients.
Scancell joins NHS cancer vaccine programme to expand melanoma trial access
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has partnered with the NHS Cancer Vaccine Launch Pad to accelerate recruitment for the next phase of its clinical trial in advanced melanoma. The company said on Monday that eligible NHS patients will be fast-tracked into the fourth cohort of its ongoing phase II SCOPE study, which is evaluating iSCIB1+, a DNA-based cancer vaccine delivered intradermally.
Scancell to showcase promising melanoma trial results at AACR cancer conference
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) will present early results from its phase II melanoma trial at next month's American Association for Cancer Research (AACR) annual meeting in Chicago. The UK-based biotech is developing SCIB1, a DNA-based cancer vaccine designed to trigger a strong and lasting immune response in patients with advanced melanoma.
Scancell phase II melanoma data to be presented at leading cancer conference
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) will present new findings from its ongoing phase II clinical trial at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference in Los Angeles from 23-26 February. The data will highlight how its experimental melanoma vaccine, SCIB1, is working in combination with two widely used cancer drugs, nivolumab and ipilimumab.
Scancell CEO on key 2025 milestones and strategy - ICYMI
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L'Huillier talked with Proactive about the company's latest interim results and its progress in 2025. He highlighted five key updates, including the latest data from the SCOPE study, which investigates the company's cancer vaccine for melanoma.
Scancell Holdings' interims 'highlight continued progress', says broker
Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) interim results highlight continued progress in its cancer vaccine pipeline, with multiple data readouts expected before the end of 2025, according to Panmure Liberum. Reiterating its 'buy' advice and 24p a share price target, the brokerage noted that early data releases have helped to reduce some of the risks associated with the programmes.
Scancell interims reflect period of significant progress
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) made significant clinical progress in the first half of its financial year, with strong trial results for its cancer immunotherapy treatments. The company also strengthened its cash position, raising £11.3mn in December, extending its cash runway to late 2026.
Scancell underlines cancer treatment potential with early data release, says broker
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) early release of data on Modi-1 Moditope vaccine in combination with checkpoint inhibitors in head and neck cancer underlines a growing confidence in the treatment, says Panmure Liberum. The data showed a significant step up in overall response rate, albeit in small patient numbers to date but supported the continuation of the study to full recruitment.
Scancell shares trade up on Thursday on cancer vaccine's early validation
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that its Modi-1 Moditope vaccine has achieved early clinical validation in HPV-negative head and neck squamous cell carcinoma (SCCHN) patients. The vaccine reached Simon stage 1 in the Phase 2a ModiFY study, suggesting significant benefits when combined with checkpoint inhibitors like pembrolizumab, the company said in a statement.
Scancell: A rising star in oncology with upgraded prospects
Panmure Liberum has raised its target price for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) from 23.3p to 24p, reflecting optimism around the biotech firm's cancer vaccine pipeline and recent milestones. The share price adjustment (more than double the current valuation) follows Scancell's successful £11.3 million capital raise in December, extending its cash runway to the second half of 2026.
Scancell outlines plans to raise up to £9.5m to support clinical plans
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has announced plans to raise up to £9.5 million to support its clinical programmes. The funding round is made up of a placing of new shares at 10.5p each that will bring in at least £8.5 million and a retail offer of stock.
